132 related articles for article (PubMed ID: 24326947)
1. Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach.
Gavious A; Greenberg D; Hammerman A; Segev E
Eur J Health Econ; 2014 Jun; 15(5):553-61. PubMed ID: 24326947
[TBL] [Abstract][Full Text] [Related]
2. Estimating the budget impact of new technologies added to the National List of Health Services in Israel: stakeholders' incentives for adopting a financial risk-sharing mechanism.
Hammerman A; Greenberg D
Health Policy; 2009 Jan; 89(1):78-83. PubMed ID: 18579253
[TBL] [Abstract][Full Text] [Related]
3. Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests.
Hammerman A; Feder-Bubis P; Greenberg D
Value Health; 2012; 15(5):737-42. PubMed ID: 22867784
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success.
Mahjoub R; Ødegaard F; Zaric GS
Health Econ; 2018 Jan; 27(1):e15-e25. PubMed ID: 28627808
[TBL] [Abstract][Full Text] [Related]
5. Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel.
Triki N; Ash N; Porath A; Birnbaum Y; Greenberg D; Hammerman A
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):749-753. PubMed ID: 31825682
[No Abstract] [Full Text] [Related]
6. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
Towse A; Garrison LP
Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
[TBL] [Abstract][Full Text] [Related]
7. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
Zaric GS; O'brien BJ
Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
[TBL] [Abstract][Full Text] [Related]
8. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
Zaric GS; Xie B
Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
[TBL] [Abstract][Full Text] [Related]
9. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
10. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States.
Brown JD; Sheer R; Pasquale M; Sudharshan L; Axelsen K; Subedi P; Wiederkehr D; Brownfield F; Kamal-Bahl S
Value Health; 2018 Jan; 21(1):33-40. PubMed ID: 29304938
[TBL] [Abstract][Full Text] [Related]
11. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
Adamski J; Godman B; Ofierska-Sujkowska G; Osińska B; Herholz H; Wendykowska K; Laius O; Jan S; Sermet C; Zara C; Kalaba M; Gustafsson R; Garuolienè K; Haycox A; Garattini S; Gustafsson LL
BMC Health Serv Res; 2010 Jun; 10():153. PubMed ID: 20529296
[TBL] [Abstract][Full Text] [Related]
12. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry.
Barros PP
Health Econ; 2011 Apr; 20(4):461-70. PubMed ID: 21394816
[TBL] [Abstract][Full Text] [Related]
13. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
Critchley GJ; Zaric GS
Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
[TBL] [Abstract][Full Text] [Related]
14. Stakeholders' feedback on the proposed recommendations for updating the patented medicine prices review board (pmprb) budget impact analysis guidelines.
Foroutan N; Tarride JE; Xie F; Jameel B; Mills F; Levine M
J Popul Ther Clin Pharmacol; 2020 Jan; 27(1):e1-e24. PubMed ID: 31922700
[TBL] [Abstract][Full Text] [Related]
15. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
[TBL] [Abstract][Full Text] [Related]
16. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
Hammerman A; Greenberg D
Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
[TBL] [Abstract][Full Text] [Related]
17. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.
Neumann PJ; Chambers JD; Simon F; Meckley LM
Health Aff (Millwood); 2011 Dec; 30(12):2329-37. PubMed ID: 22147861
[TBL] [Abstract][Full Text] [Related]
18. When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing.
Balderrama F; Schwartz LJ; Longo CJ
Health Care Anal; 2020 Jun; 28(2):121-136. PubMed ID: 32232611
[TBL] [Abstract][Full Text] [Related]
19. Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience.
Grocott R
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):181-7. PubMed ID: 19402806
[TBL] [Abstract][Full Text] [Related]
20. Financial risk relationships and adoption of management strategies in physician groups for self-administered injectable drugs.
Agnew JD; Stebbins MR; Hickman DE; Lipton HL
J Manag Care Pharm; 2003; 9(6):523-33. PubMed ID: 14664660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
